| Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
|
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
|
Nature Medicine |
Myelodysplastic Syndromes (MDS) |
| Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors |
|
PLOS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| In Search for a Haemoglobin Threshold in Myelodysplastic Syndromes |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database |
|
Annals of Hematology |
Aplastic Anemia |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria |
|
Blood |
Aplastic Anemia |
| Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
|
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
